Adenovirus-vectored vaccine manufacturing production and purification process

Applications: Biologics, Vaccines, Adenovirus

Improved manufacturing and purification methods for adenoviral vector vaccines, oncolytic viruses, and gene therapies to achieve high titre at low production costs. These techniques are particularly suited for scaling up vaccine production for emergency use.

Features	Benefits
Efficient Scale-Up Elimination of production bottlenecks Process simplifications	Successful scale-up from 3L -> 1000L -> 4000L Enabling rapid response to global demand
Novel downstream process optimisations Advanced tangential flow filtration (TFF) Direct-load anion exchange chromatography (AEX)	Allows removal of an extra TFF step Improved purification efficiency and yield
Productivity Enhancements	Significant increase in virus particle (VP) production (figure 1) Effectively scaled 2000L run for commercial manufacturing (figure 1)
Cost-Effective Production (figure 2)	Reduced manufacturing costs for vaccines Increased feasibility for global distribution, particularly in low- and middle-income countries

Patent pending and available for licensing.

Request more information
about this technology

Back to Technologies Available

Technologies for License

Adenovirus-vectored vaccine manufacturing production and purification process

Ready to get in touch?